Ethnopsychopharmacology

References

• Aklillu E, Persson I, Bertilsson L, Johansson I, Rodrigues F, Ingelman-Sundberg M. Frequent distribution of ultrarapid metabolizers of debrisoquine in an ethiopian population carrying duplicated and multiduplicated functional CYP2D6 alleles. The Journal of Pharmacology and Experimental Therapeutics 1996; 278: 441–446
   PubMed Web of Science ®Google Scholar
• Allen JJ, Rack PH, Vaddadi KS. Differences in the effects of clomipramine on English and Asian volunteers. Preliminary report on a pilot study. Postgraduate Medical Journal 1977; 53: S79–S86
   PubMed Web of Science ®Google Scholar
• Anderson KE, Kappas A. Dietary regulation of cytochrome P450. Annual Review of Nutrition 1991; 11: 141–167
   PubMed Web of Science ®Google Scholar
• Arias B, Catalan R, Gasto C, Gutierrez B, Fananas L. 5-HTTLPR polymorphism of the serotonin transporter gene predicts non-remission in major depression patients treated with citalopram in a 12-weeks follow up study. Journal of Clinical Psychopharmacology 2003; 23: 563–567
   PubMed Web of Science ®Google Scholar
• Beratis S, Katrivanou A, Gourzis P. Factors affecting smoking in schizophrenia. Comprehensive Psychiatry 2001; 42: 393–402
   PubMed Web of Science ®Google Scholar
• Branch RA, Salih SY, Homeida M. Racial differences in drug metabolizing ability: A study with antipyrine in the Sudan. Clinical Pharmacology and Therapeutics 1978; 24: 283–286
   PubMed Web of Science ®Google Scholar
• Choi JY, Lee KM, Cho SH, Kim SW, Choi HY, Lee SY, et al. CYP2E1 and NQO1 genotypes, smoking and bladder cancer. Pharmacogenetics 2003; 13: 349–355
   PubMedGoogle Scholar
• Dahl ML, Yue QY, Roh HK, Johansson I, Sawe J, Sjoqvist F, et al. Genetic analysis of the CYP2D locus in relation to debrisoquine hydroxylation capacity in Korean, Japanese and Chinese subjects. Pharmacogenetics 1995; 5: 159–164
   PubMedGoogle Scholar
• Daly AK, Brockmoller J, Broly F, Eichelbaum M, Evans WE, Gonzalez FJ, et al. Nomenclature for human CYP2D6 alleles. Pharmacogenetics 1996; 6: 193–201
   PubMedGoogle Scholar
• de Morais SM, Wilkinson GR, Blaisdell J, Nakamura K, Meyer UA, Goldstein JA. The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans. The Journal of Biological Chemistry 1994; 269: 15419–15422
   PubMed Web of Science ®Google Scholar
• Fraser HS, Mucklow JC, Bulpitt CJ, Kahn C, Mould G, Dollery CT. Environmental factors affecting antipyrine metabolism in London factory and office workers. British Journal of Clinical Pharmacology 1979; 7: 237–243
   PubMed Web of Science ®Google Scholar
• Fuhr U, Klittich K, Staib AH. Inhibitory effect of grapefruit juice and its bitter principal, naringenin, on CYP1A2 dependent metabolism of caffeine in man. British Journal of Clinical Pharmacology 1993; 35: 431–436
   PubMed Web of Science ®Google Scholar
• Gelernter J, Kranzler H, Cubells JF. Serotonin transporter protein (SLC6A4) allele and haplotype frequencies and linkage disequilibria in African- and European-American and Japanese populations and in alcohol-dependent subjects. Human Genetics 1997; 101: 243–246
   PubMed Web of Science ®Google Scholar
• Goldstein JA, Ishizaki T, Chiba K, de Morais SM, Bell D, Krahn PM, et al. Frequencies of the defective CYP2C19 alleles responsible for the mephenytoin poor metabolizer phenotype in various Oriental, Caucasian, Saudi Arabian and American black populations. Pharmacogenetics 1997; 7: 59–64
   PubMedGoogle Scholar
• Greenberg BD, McMahon FJ, Murphy DL. Serotonin transporter candidate gene studies in affective disorders and personality: Promises and potential pitfalls. Molecular Psychiatry 1998; 3: 186–189
   PubMed Web of Science ®Google Scholar
• Hariri AR, Weinberger DR. Functional neuroimaging of genetic variation in serotonergic neurotransmission. Genes, Brain and Behavior 2003; 2: 341–349
   PubMed Web of Science ®Google Scholar
• Jurima-Romet M, Crawford K, Cyr T, Inaba T. Terfenadine metabolism in human liver. In vitro inhibition by macrolide antibiotics and azole antifungals. Drug Metabolism and Disposition 1994; 22: 849–857
   PubMed Web of Science ®Google Scholar
• Kelly C, McCreadie RG. Smoking habits, current symptoms, and premorbid characteristics of schizophrenic patients in Nithsdale, Scotland. American Journal of Psychiatry 1999; 156: 1751–1757
   PubMed Web of Science ®Google Scholar
• Kim H, Lim SW, Kim S, Kim JW, Chang YH, Carroll BJ, et al. Monoamine transporter gene polymorphisms and antidepressant response in Koreans with late-life depression. The Journal of the American Medical Association 2006; 296: 1609–1618
   PubMed Web of Science ®Google Scholar
• Le Marchand L, Sivaraman L, Pierce L, Seifried A, Lum A, Wilkens LR, et al. Associations of CYP1A1, GSTM1, and CYP2E1 polymorphisms with lung cancer suggest cell type specificities to tobacco carcinogens. Cancer Research 1998; 58: 4858–4863
   PubMed Web of Science ®Google Scholar
• Leathart JB, London SJ, Steward A, Adams JD, Idle JR, Daly AK. CYP2D6 phenotype-genotype relationships in African-Americans and Caucasians in Los Angeles. Pharmacogenetics 1998; 8: 529–541
   PubMedGoogle Scholar
• Li T, Vallada H, Curtis D, Arranz M, Xu K, Cai G, et al. Catechol-O-methyltransferase Val158Met polymorphism: Frequency analysis in Han Chinese subjects and allelic association of the low activity allele with bipolar affective disorder. Pharmacogenetics 1997; 7: 349–353
   PubMedGoogle Scholar
• Lin KM, Poland RE. Ethnicity, Culture, and Psychopharmacology in Psychopharmacology: The Fourth Generation of Progress. Raven Press, New York 1995
   Google Scholar
• Lin KM, Poland RE, Lau JK, Rubin RT. Haloperidol and prolactin concentrations in Asians and Caucasians. Journal of Clinical Psychopharmacology 1988; 8: 195–201
   PubMed Web of Science ®Google Scholar
• Lin KM, Poland RE, Nakasaki G. Psychopharmacology and Psychobiology of Ethnicity. American Psychiatric Press, Washington DC 1993
   Google Scholar
• Lin KM, Poland RE, Nuccio I, Matsuda K, Hathuc N, Su TP, et al. A longitudinal assessment of haloperidol doses and serum concentrations in Asian and Caucasian schizophrenic patients. American Journal of Psychiatry 1989; 146: 1307–1311
   PubMed Web of Science ®Google Scholar
• Liou YH, Lin CT, Wu YJ, Wu LS. The high prevalence of the poor and ultrarapid metabolite alleles of CYP2D6, CYP2C9, CYP2C19, CYP3A4, and CYP3A5 in Taiwanese population. American Journal of Human Genetics 2006; 51: 857–863
   Google Scholar
• Lohr JB, Flynn K. Smoking and schizophrenia. Schizophrenia Research 1992; 8: 93–102
   PubMed Web of Science ®Google Scholar
• Masimirembwa CM, Hasler JA. Genetic polymorphism of drug metabolising enzymes in African populations: Implications for the use of neuroleptics and antidepressants. Brain Research Bulletin 1997; 44: 561–571
   PubMed Web of Science ®Google Scholar
• McLeod HL, Fang L, Luo X, Scott EP, Evans WE. Ethnic differences in erythrocyte catechol-O-methyltransferase activity in black and white Americans. The Journal of Pharmacology and Experimental Therapeutics 1994; 270: 26–29
   PubMed Web of Science ®Google Scholar
• Mendoza R, Wan YJ, Poland RE, Smith M, Zheng Y, Berman N, et al. CYP2D6 polymorphism in a Mexican American population. Clinical Pharmacology and Therapeutics 2001; 70: 552–560
   PubMed Web of Science ®Google Scholar
• Miller LG. Recent developments in the study of the effects of cigarette smoking on clinical pharmacokinetics and clinical pharmacodynamics. Clinical Pharmacokinetics 1989; 17: 90–108
   PubMed Web of Science ®Google Scholar
• Ng J, Lin KM, Smith M. Perspectives in Cross-Cultural Psychiatry. Lippincott Williams & Wilkins, Philadelphia 2005
   Google Scholar
• Oesterheld J, Kallepalli BR. Grapefruit juice and clomipramine: Shifting metabolitic ratios. Journal of Clinical Psychopharmacology 1997; 17: 62–63
   PubMed Web of Science ®Google Scholar
• Pollock BG, Ferrell RE, Mulsant BH, Mazumdar S, Miller M, Sweet RA, et al. Allelic variation in the serotonin transporter promoter affects onset of paroxetine treatment response in late-life depression. Neuropsychopharmacology 2000; 23: 587–590
   PubMed Web of Science ®Google Scholar
• Rausch JL, Johnson ME, Fei YJ, Li JQ, Shendarkar N, Hobby HM, et al. Initial conditions of serotonin transporter kinetics and genotype: Influence on SSRI treatment trial outcome. Biological Psychiatry 2002; 51: 723–732
   PubMed Web of Science ®Google Scholar
• Rivera-Calimlim L, Reilly DK. Difference in erythrocyte catechol-O-methyltransferase activity between Orientals and Caucasians: Difference in levodopa tolerance. Clinical Pharmacology and Therapeutics 1984; 35: 804–809
   PubMed Web of Science ®Google Scholar
• Roby CA, Anderson GD, Kantor E, Dryer DA, Burstein AH. St John's Wort: Effect on CYP3A4 activity. Clinical Pharmacology and Therapeutics 2000; 67: 451–457
   PubMed Web of Science ®Google Scholar
• Schein JR. Cigarette smoking and clinically significant drug interactions. The Annals of Pharmacotherapy 1995; 29: 1139–1148
   PubMed Web of Science ®Google Scholar
• Schildkraut JJ, Kopin IJ, Schanberg SM, Durell J. Norepinephrine metabolism and psychoactive drugs in the endogenous depressions. 1968. Pharmacopsychiatry 1995; 28: 24–37
   PubMedGoogle Scholar
• Smeraldi E, Zanardi R, Benedetti F, Di Bella D, Perez J, Catalano M. Polymorphism within the promoter of the serotonin transporter gene and antidepressant efficacy of fluvoxamine. Molecular Psychiatry 1998; 3: 508–511
   PubMed Web of Science ®Google Scholar
• Wang SL, Huang JD, Lai MD, Liu BH, Lai ML. Molecular basis of genetic variation in debrisoquin hydroxylation in Chinese subjects: Polymorphism in RFLP and DNA sequence of CYP2D6. Clinical Pharmacology and Therapeutics 1993; 53: 410–418
   PubMed Web of Science ®Google Scholar
• Weinberger DR, Egan MF, Bertolino A, Callicott JH, Mattay VS, Lipska BK, et al. Prefrontal neurons and the genetics of schizophrenia. Biological Psychiatry 2001; 50: 825–828
   PubMed Web of Science ®Google Scholar
• Xie HG, Stein CM, Kim RB, Wilkinson GR, Flockhart DA, Wood AJ. Allelic, genotypic and phenotypic distributions of S-mephenytoin 4′-hydroxylase (CYP2C19) in healthy Caucasian populations of European descent throughout the world. Pharmacogenetics 1999; 9: 539–549
   PubMedGoogle Scholar
• Yoshida K, Ito K, Sato K, Takahashi H, Kamata M, Higuchi H, et al. Influence of the serotonin transporter gene-linked polymorphic region on the antidepressant response to fluvoxamine in Japanese depressed patients. Progress in Neuro-psychopharmacology & Biological Psychiatry 2002; 26: 383–386
   PubMed Web of Science ®Google Scholar
• Yu YW, Tsai SJ, Chen TJ, Lin CH, Hong CJ. Association study of the serotonin transporter promoter polymorphism and symptomatology and antidepressant response in major depressive disorders. Molecular Psychiatry 2002; 7: 1115–1119
   PubMed Web of Science ®Google Scholar
• Zanardi R, Serretti A, Rossini D, Franchini L, Cusin C, Lattuada E, et al. Factors affecting fluvoxamine antidepressant activity: Influence of pindolol and 5-HTTLPR in delusional and nondelusional depression. Biological Psychiatry 2001; 50: 323–330
   PubMed Web of Science ®Google Scholar
• Zevin S, Benowitz NL. Drug interactions with tobacco smoking. An update. Clinical Pharmacokinetics 1999; 36: 425–438
   PubMed Web of Science ®Google Scholar